Microcap Ledger AN2 Therapeutics, Inc. $ANTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Menlo Park, CA
- Fiscal year end
- December 31
- Shares outstanding
- 37,736,237 [10-Q 2026-08-11]
What the company doesAI summary of filing
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics based on its boron chemistry platform. The company's lead program, epetraborole, is in Phase 2 development for polycythemia vera and mycobacterium abscessus complex lung disease, while AN2-502998 is in Phase 1 trials for Chagas disease. The company does not generate product revenue and relies on third-party contract manufacturers; it funds operations through equity financing and non-dilutive grants for global health programs targeting infectious diseases and oncology. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$18.20M | −$19.07M | $44.32M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$35.17M | −$29.83M | $19.94M | [10-K 2026-03-17] |
| FY ended Dec 2024 | — | −$51.32M | −$49.26M | $21.35M | [10-K 2026-03-17] |
- Quarterly cash burn
- −$9.54M
- Cash runway Estimate
- ~13.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 29,878,890 | [10-Q 2024-11-13] |
| 2025-03-20 | 30,098,720 | [10-K 2025-03-25] |
| 2025-05-05 | 30,175,720 | [10-Q 2025-05-13] |
| 2025-08-04 | 27,326,165 | [10-Q 2025-08-12] |
| 2025-11-03 | 27,402,024 | [10-Q 2025-11-12] |
| 2026-03-10 | 35,941,195 | [10-K 2026-03-17] |
| 2026-05-07 | 36,016,161 | [10-Q 2026-05-11] |
| 2026-08-06 | 37,736,237 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-04-09; declared effective 2026-04-20 [S-3 2026-04-09]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Trenor Cameron C. Iii | grant | 116,667 | — | [4 2026-09-16] |
| 2026-09-09 | Readnour Robin Shane | sell | 523 | $6.02 | [4 2026-09-11] |
| 2026-09-09 | Readnour Robin Shane | sell | 585 | $6.02 | [4 2026-09-11] |
| 2026-09-08 | Readnour Robin Shane | sell | 4,725 | $6.02 | [4 2026-09-08] |
| 2026-09-08 | Readnour Robin Shane | sell | 5,294 | $6.02 | [4 2026-09-08] |
| 2026-09-03 | Readnour Robin Shane | sell | 2,877 | $6.07 | [4 2026-09-08] |
| 2026-09-03 | Readnour Robin Shane | sell | 3,223 | $6.07 | [4 2026-09-08] |
| 2026-09-01 | Williams Sarah Joanne | sell | 272 | $5.53 | [4 2026-09-04] |
| 2026-09-01 | Fitzpatrick Margaret M | buy | 2,098 | $5.53 | [4 2026-09-02] |
| 2026-08-17 | Readnour Robin Shane | sell | 16,696 | $6.01 | [4 2026-08-19] |
| 2026-08-17 | Readnour Robin Shane | sell | 18,706 | $6.01 | [4 2026-08-19] |
| 2026-08-14 | Zakrzewski Joseph S | other | 405,880 | — | [4 2026-08-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-06-09 | 8-K | Shareholder vote results |
| 2026-06-04 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-04-22 | DEF 14A | Proxy statement |
| 2026-04-20 | 424B3 | Prospectus or prospectus supplement |
| 2026-04-20 | 424B5 | Prospectus or prospectus supplement |
| 2026-04-09 | S-3 | Registration statement |
| 2026-04-09 | 8-K | Other events |
Alerts for $ANTX
Email me when AN2 Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.